Understanding the links between lung cancer, COPD, and emphysema: A key to more effective treatment and screening

ONCOLOGY (United States)

Volumn 31, Issue 2, 2017, Pages

  Seijo, Luis M ^a   Zulueta, Javier J ^b,c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; VASCULOTROPIN RECEPTOR 1;

AIRWAY OBSTRUCTION; CANCER PROGNOSIS; CANCER SCREENING; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DNA DAMAGE; DNA REPAIR; EMPHYSEMA; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LUNG CANCER; LUNG FUNCTION; REVIEW; RISK FACTOR;

EID: 85015279409     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;172:523-9.
2. Shlomi D, Ben-Avi R, Balmor GR, et al. Screening for lung cancer: time for large-scale screening by chest computed tomography. Eur Respir J. 2014;44:217-38.
3. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117-71.
4. Houghton AM, Mouded M, Shapiro SD. Common origins of lung cancer and COPD. Nat Med. 2008;14:1023-4.
5. Turner MC, Chen Y, Krewski D, et al. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med. 2007;176:285-90.
6. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med. 1986;105:503-7.
7. Tockman MS, Anthonisen NR, Wright EC, Donithan MG. Airways obstruction and the risk for lung cancer. Ann Intern Med. 1987;106:512-8.
8. de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest. 2007;132:1932-8.
9. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med. 2008;178:738-44.
10. Maldonado F, Bartholmai BJ, Swensen SJ, et al. Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis. Chest. 2010;138:1295-302.
11. Lowry KP, Gazelle GS, Gilmore ME, et al. Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: a decision analysis. Cancer. 2015;121:1556-62.
12. Wasswa-Kintu S, Gan WQ, Man SF, et al. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax. 2005;60:570-5.
13. Powell HA, Iyen-Omofoman B, Baldwin DR, et al. Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. J Thorac Oncol. 2013;8:6-11.
14. de Torres JP, Marín JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease-incidence and predicting factors. Am J Respir Crit Care Med. 2011;184:913-9.
15. Sanchez-Salcedo P, Berto J, de-Torres JP, et al. Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP). Arch Bronconeumol. 2015;51:169-76.
16. Calabrò E, Randi G, La Vecchia C, et al. Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes. Eur Respir J. 2010;35:146-51.
17. Mannino DM, Aguayo SM, Petty TL, et al. Low lung function and incident lung cancer in the United States: data from the first National Health and Nutrition Examination Survey follow-up. Arch Intern Med. 2003;163:1475-80.
18. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung cancer death. N Engl J Med. 2013;369:245-54.
19. Sanchez-Salcedo P, Wilson DO, de-Torres JP, et al. Improving selection criteria for lung cancer screening: the potential role of emphysema. Am J Respir Crit Care Med. 2015;191:924-31.
20. Henschke CI, Yip R, Boffetta P, et al. CT screening for lung cancer: importance of emphysema for never smokers and smokers. Lung Cancer. 2015;88:42-7.
21. Kwak N, Park CM, Lee J, et al. Lung cancer risk among patients with combined pulmonary fibrosis and emphysema. Respir Med. 2014;108:524-30.
22. Zulueta JJ, Wisnivesky JP, Henschke CI, et al. Emphysema scores predict death from COPD and lung cancer. Chest. 2012;141:1216-23.
23. Li Y, Swensen SJ, Karabekmez LG, et al. Effect of emphysema on lung cancer risk in smokers: a computed tomography-based assessment. Cancer Prev Res. 2011;4:43-50.
24. Kishi K, Gurney JW, Schroeder DR, et al. The correlation of emphysema or airway obstruction with the risk of lung cancer: a matched case-controlled study. Eur Respir J. 2002;19:1093-8.
25. Smith BM, Pinto L, Ezer N, et al. Emphysema detected on computed tomography and risk of lung cancer: a systematic review and meta-analysis. Lung Cancer. 2012;77:58-63.
26. Hohberger LA, Schroeder DR, Bartholmai BJ, et al. Correlation of regional emphysema and lung cancer: a lung tissue research consortium-based study. J Thorac Oncol. 2014;9:639-45.
27. Bishawi M, Moore W, Bilfinger T. Severity of emphysema predicts location of lung cancer and 5-y survival of patients with stage I non-small cell lung cancer. J Surg Res. 2013;184:1-5.
28. Kinsey CM, San José Estépar R, Wei Y, et al. Regional emphysema of a non-small cell tumor is associated with larger tumors and decreased survival rates. Ann Am Thorac Soc. 2015;12:1197-205.
29. Bremnes RM, Dønnem T, Al-Saad S, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011;6:209-17.
30. Murakami J, Ueda K, Sano F, et al. Pulmonary emphysema and tumor microenvironment in primary lung cancer. J Surg Res. 2016;200:690-7.
31. Schwartz AG, Ruckdeschel JC. Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:16-22.
32. Yang P, Sun Z, Krowka MJ, et al. α1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med. 2008;168:1097-103.
33. Pillai SG, Kong X, Edwards LD, et al. Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:1498-505.
34. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638-42.
35. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q 25. Nature. 2008;452:633-7.
36. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40:616-22.
37. Hosgood HD III, Cawthon R, Xingzhou H, et al. Genetic variation in telomere maintenance genes, telomere length, and lung cancer susceptibility. Lung Cancer. 2009;66:157-61.
38. Alder JK, Guo N, Kembou F, et al. Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med. 2011;184:904-12.
39. Savale L, Chaouat A, Bastuji-Garon S, et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179:566-71.
40. Frías C, García-Aranda C, De Juan C, et al. Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. Lung Cancer. 2008;60:416-25.
41. Gao L, Thakur A, Liang Y, et al. Polymorphisms in the TERT gene are associated with lung cancer risk in the Chinese Han population. Eur J Cancer Prev. 2014;23:497-501.
42. Wang H, Yang L, Deng J, et al. Genetic variant in the 3’-untranslated region of VEGFR1 gene influences chronic obstructive pulmonary disease and lung cancer development in Chinese population. Mutagenesis. 2014;29:311-7.
43. Van Dyke AL, Cote ML, Wenzlaff AS, et al. Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev. 2009;18:1829-40.
44. Young RP, Hopkins RJ, Hay BA, et al. FAM13A locus in COPD is independently associated with lung cancer—evidence of a molecular genetic link between COPD and lung cancer. Appl Clin Genet. 2011;4:1-10.
45. Sato T, Arai E, Kohno T, et al. Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: its correlation with smoking history and chronic obstructive pulmonary disease. Int J Cancer. 2014;135:319-34.
46. Tessema M, Yingling CM, Picchi MA, et al. Epigenetic repression of CCDC37 and MAP1B links chronic obstructive pulmonary disease to lung cancer. J Thorac Oncol. 2015;10:1181-8.
47. Leidinger P, Keller A, Borries A, et al. Specific peripheral miRNA profiles for distinguishing lung cancer from COPD. Lung Cancer. 2011;74:41-7.
48. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 2010;31:37-49.
49. Roos AB, Sandén C, Mori M, et al. IL-17A is elevated in end-stage chronic obstructive pulmonary disease and contributes to cigarette smoke-induced lymphoid neogenesis. Am J Respir Crit Care Med. 2015;191:1232-41.
50. Yang B, Kang H, Fung A, et al. The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm. 2014;2014:623759.
51. Nguyen AH, Berim IG, Agrawal DK. Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol. 2014;10:1711-30.
52. Neurath MF, Finotto S. The emerging role of T cell cytokines in non-small cell lung cancer. Cytokine Growth Factor Rev. 2012;23:315-22.
53. Gocheva V, Wang HW, Gadea BB, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010;24:241-55.
54. Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc. 2007;4:512-21.
55. Ito N, Suzuki Y, Taniguchi Y, et al. Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Res. 2005;25:2027-31.
56. Shen HM, Tergaonkar V. NFB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis. 2009;14:348-63.
57. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749-59.
58. Kaisari S, Rom O, Aizenbud D, Reznick AZ. Involvement of NF-κB and muscle specific E3 ubiquitin ligase MuRF1 in cigarette smoke-induced catabolism in C2 myotubes. Adv Exp Med Biol. 2013;788:7-17.
59. Wright JG, Christman JW. The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med. 2003;2:211-9.
60. Gadgeel SM, Wozniak A. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin Lung Cancer. 2013;14:322-32.
61. Stark AK, Sriskantharajah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharmacol. 2015;23:82-91.
62. de Boer WI, Hau CM, van Schadewijk A, et al. Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol. 2006;125:184-92.
63. Lim JU, Yeo CD, Rhee CK, et al. Chronic obstructive pulmonary disease-related non-small-cell lung cancer exhibits a low prevalence of EGFR and ALK driver mutations. PLoS One. 2015;10:e0142306.
64. Vallath S, Hynds R, Succony L, et al. Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities. Eur Respir J. 2014;44:513-22.
65. Baarsma HA, Spanjer AI, Haitsma G, et al. Activation of WNT/β-catenin signaling in pulmonary fibroblasts by TGF-α1 is increased in chronic obstructive pulmonary disease. PLoS One. 2011;6:e25450.
66. Pacheco-Pinedo EC, Durham AC, Stewart KM, et al. Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest. 2011;121:1935-45.
67. Stewart DJ. Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. 2014;106:djt356.
68. Kneidinger N, Önder Yildirim A, Callegari J, et al. Activation of the WNT/β-catenin pathway attenuates experimental emphysema. Am J Respir Crit Care Med. 2011;183:723-33.
69. Sohal S, Reid D, Soltani A, et al. Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease. Respir Res. 2011;12:130.
70. Wang H, Zhang H, Tang L, et al. Resveratrol inhibits TGF-1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis. Toxicology. 2013;303:139-46.
71. Yang L, Yang X, Ji W, et al. Effects of a functional variant c.353T>C in Snai1 on risk of two contextual diseases: chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med. 2014;189:139-48.
72. Gao YH, Guan WJ, Liu Q, et al. Impact of COPD and emphysema on survival of patients with lung cancer: a meta-analysis of observational studies. Respirology. 2016;21:269-79.
73. Young RP, Duan F, Chiles C, et al. Airflow limitation and histology shift in the National Lung Screening Trial. The NLST-ACRIN Cohort Substudy. Am J Respir Crit Care Med. 2015;192:1060-7.
74. Wille MM, Dirksen A, Ashraf H, et al. Results of the randomized Danish Lung Cancer Screening Trial with focus on high-risk profiling. Am J Respir Crit Care Med. 2016;193:542-51.
75. Moyer VA; US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:330-8.
76. Kauczor HU, Bonomo L, Gaga M, et al. ESR/ERS white paper on lung cancer screening. Eur Respir J. 2015;46:28-39.
77. Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012;144:33-8.
78. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN®). Lung cancer screening. Version 1. 2017. https://www.nccn.org/professionals/physician_gls/pdf/lung-screening.pdf. Accessed January 31, 2017.
79. Wender R, Fontham ET, Barrera E Jr, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63:107-17.
80. Detterbeck FC, Mazzone PJ, Naidich DP, et al. Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(suppl 5):e78S-e92S.
81. Wang Y, Midthun DE, Wampfler JA, et al. Trends in the proportion of lung cancer patients meeting screening criteria. JAMA. 2015;313:853-5.
82. Pinsky PF, Berg CD. Applying the National Lung Screening Trial eligibility criteria to the US population: What percent of the population and of incident lung cancers would be covered? J Med Screen. 2012;19:154-6.
83. Maisonneuve P, Bagnardi V, Bellomi M, et al. Lung cancer risk prediction to select smokers for screening CT-a model based on the Italian COSMOS trial. Cancer Prev Res. 2011;4:1778-89.
84. de-Torres JP, Wilson DO, Sanchez-Salcedo P, et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med. 2015;191:285-91.
85. Wang G, Wang L, Ma Z, et al. Quantitative emphysema assessment of pulmonary function impairment by computed tomography in chronic obstructive pulmonary disease. J Comput Assist Tomogr. 2015;39:171-5.
86. Yasunaga K, Chérot-Kornobis N, Edmé JL, et al. Emphysema in asymptomatic smokers: quantitative CT evaluation in correlation with pulmonary function tests. Diagn Interv Imaging. 2013;94:609-17.
87. de-Torres JP, Marín JM, Casanova C, et al. Identification of COPD patients at high risk for lung cancer mortality using the COPD-LUCSS-DLCO. Chest. 2016;149:936-42.
88. de-Torres JP, Casanova C, Marín JM, et al. Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. Respir Med. 2013;107:702-7.
89. Casas Herrera A, Montes de Oca M, López Varela MV, et al. COPD underdiagnosis and misdiagnosis in a high-risk primary care population in four Latin American countries. A key to enhance disease diagnosis: the PUMA study. PLoS One. 2016;11:e0152266.
90. López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21:14-23.
91. Lamprecht B, Soriano JB, Studnicka M, et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest. 2015;148:971-85.
92. Sekine Y, Fujisawa T, Suzuki K, et al. Detection of chronic obstructive pulmonary disease in community-based annual lung cancer screening: Chiba Chronic Obstructive Pulmonary Disease Lung Cancer Screening Study Group. Respirology. 2014;19:98-104.
93. Manners D, Hui J, Hunter M, et al. Estimating eligibility for lung cancer screening in an Australian cohort, including the effect of spirometry. Med J Aust. 2016;204:406.
94. Mets OM, Schmidt M, Buckens CF, et al. Diagnosis of chronic obstructive pulmonary disease in lung cancer screening computed tomography scans: independent contribution of emphysema, air trapping and bronchial wall thickening. Respir Res. 2013;14:59.
95. Mets OM, Buckens CF, Zanen P, et al. Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans. JAMA. 2011;306:1775-81.
96. Wille MM, Thomsen LH, Dirksen A, et al. Emphysema progression is visually detectable in low-dose CT in continuous but not in former smokers. Eur Radiol. 2014;24:2692-9.
97. American Academy of Family Physicians. Lung cancer clinical recommendations. http://www.aafp.org/patient-care/clinical-recommendations/all/lung-cancer.html. Accessed September 9, 2016.
98. Smith RA, Andrews K, Brooks D, et al. Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2016;66:96-114.
99. Bach PB, Mirkin JN, Oliver TK. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307:2418-29.
100. American Lung Association. Providing guidance on lung cancer screening to patients and physicians. An update from the American Lung Association Screening Committee. April 30, 2015.